NVS Novartis AG

   By Joshua Kirby 
 

Novartis AG said Tuesday that its drug Beovu showed positive results in the Phase-3 KESTREL study, with the trial meeting its primary endpoint.

Beovu, a treatment for diabetic macular edema, met the primary endpoint of non-inferiority in change in best-corrected visual acuity from aflibercept 2 mg after a year, the Swiss pharmaceutical company said. The trial also met its key secondary endpoint of non-inferiority in average change in BCVA at week 40 through week 52 of the trial, Novartis said.

The findings from this and a previous trial will be submitted to health authorities in the first half of next year, the company added.

Write to Joshua Kirby at joshua.kirby@dowjones.com; @joshualeokirby

(END) Dow Jones Newswires

December 15, 2020 01:54 ET (06:54 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.